Gagomers - Novel drug delivery system for the delivery of proteins to the brain

The Invention Gagomers are novel particles (neither liposomes nor microspheres/nanospheres) composed of hyaluronan shell which is crossed linked via phospholipids. Gagomers could be generated either as micro or nano particles. The research team at Tel Aviv University has demonstrated the ability of Gagomers to encapsulate various proteins ranging from ~ 11,000 KDa (Insulin) to ~50,000 KDa (BSA). Gagomers encapsulating a specific protein in the size of ~50,000 KDa were tested in vivo showing penetration to the brain following an Intra-Nasal administration. Penetration to the brain was significantly increased when comparing to the native protein. Moreover, the protein kept its biological activity as assayed in the brain homogenate.

In addition to their ability to deliver proteins to the brain, Gagomers were demonstrated to encapsulate DNA, proteins and small molecules with high efficiency and perform in vivo as targeted, site-adherent; site-retained, sustained-release drug depots. Gagomers entrapping chemotherapeutics were proved to be long-circulating, actively target their entrapped drugs to tumors, and significantly improve clinical indicators such as circulating time, tumor size, tumor growth rate and long-term survival.

Potential Applications 1) Delivery system for the treatment of various brain diseases 2) In vivo imaging 3) Gene therapy
Advantages - Provide Intra-Nasal administration of large proteins - Biocompatible - Initial safety studies indicates a safe preparation - Biodegradable Stage Protein delivery to the brain, via intranasal administration (bypassing the BBB through the olfactory bulb): In vivo proof of concept obtained. High encapsulation efficiency. Cumulative structural and physicochemical characterization and formulation of a wide rang of drugs: DNA, small molecule drugs, peptides and proteins. Extensive mechanistic and functional in vitro and in vivo studies, showing among other aspects that these particles facilitate and increase drug entry into target cells, and that the system is not toxic.
Patent Pending applications in US, EP and selected countries in the Far East.

Inventor(s): Rimona Margalit, Dan Peer

Type of Offer: Licensing



Next Patent »
« More Pharmaceutical Patents

Share on      


CrowdSell Your Patent